(1S)-2-amino-1-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)ethanol | 384340-07-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并二恶烷
• 英文名称: (1S)-2-amino-1-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)ethanol
• 英文别名: (S)-2-Amino-1-(2,2-dimethyl-4H-benzo[d][1,3]dioxin-6-yl)ethanol
• CAS: 384340-07-2
• 化学式: C₁₂H₁₇NO₃
• 分子量: 223.272
• InChiKey: XTAAANMPVNIYBF-SNVBAGLBSA-N

物化性质

• 沸点：
  404.7±45.0 °C(Predicted)
• 密度：
  1.165±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  64.7
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (1S)-2-amino-1-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)ethanol 在 水 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 67.5h， 生成 (S)-salmeterol acetate
  参考文献：
  名称：

  Enantioselective synthesis of (S)-salmeterol via asymmetric reduction of azidoketone by Pichia angusta

  摘要：

  An efficient enantioselective route to (S)-salmeterol involving asymmetric reduction of an azidoketone intermediate to an azido alcohol by Pichia angusta is described. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0957-4166(01)00350-0
• 作为产物：
  描述：

  2-溴-1-(2,2-二甲基-4H-1,3-苯并二噁英-6-基)乙酮 在 palladium on activated charcoal sodium azide 、 Mucor racemosus 、 氢气 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 47.0h， 生成 (1S)-2-amino-1-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)ethanol
  参考文献：
  名称：

  Enantioselective synthesis of (S)-salmeterol via asymmetric reduction of azidoketone by Pichia angusta

  摘要：

  An efficient enantioselective route to (S)-salmeterol involving asymmetric reduction of an azidoketone intermediate to an azido alcohol by Pichia angusta is described. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0957-4166(01)00350-0

文献信息

• The discovery of long-acting saligenin β2 adrenergic receptor agonists incorporating hydantoin or uracil rings
  作者：Panayiotis A. Procopiou、Victoria J. Barrett、Nicola J. Bevan、Peter R. Butchers、Richard Conroy、Amanda Emmons、Alison J. Ford、Séverine Jeulin、Brian E. Looker、Gillian E. Lunniss、Valerie S. Morrison、Peter J. Mutch、Rossana Perciaccante、Mark Ruston、Claire E. Smith、Graham Somers

  DOI：10.1016/j.bmc.2011.05.064

  日期：2011.7

  A series of novel, potent and selective human β2 adrenoceptor agonists incorporating a hydantoin or a uracil ring on the right-hand side phenyl ring of (R)-salmeterol is presented. Hydantoin 12a had long duration of action in vitro on guinea pig trachea, and 12 h in guinea pigs in vivo at its EC90 25 μM. It had lower oral absorption than salmeterol in rats, and lower bioavailability than salmeterol

  β的一系列新颖的，有效的和选择性的人2结合的右手侧苯环上的乙内酰脲或尿嘧啶环肾上腺素受体激动剂（[R）-salmeterol被呈现。乙内酰脲12a在体外对豚鼠气管的作用时间长，在豚鼠体内以EC 90 25μM的作用时间为12 h 。它在大鼠中的口服吸收低于沙美特罗，并且在大鼠和狗中的体内生物利用度均低于沙美特罗（分别为2％和5％）。提出了一种改进的测量给予大鼠的类似物的吸收分数的方法，该方法考虑了葡糖醛酸化的分数。化合物12a在人肝微粒体和肝细胞中代谢为活性乙醛酸12m。
• Agonists of beta-adrenoceptors
  申请人：——

  公开号：US20040242890A1

  公开（公告）日：2004-12-02

  The present invention relates to novel compounds of formula (I), to a process for their manufacture, to pharmaceutical compositions containing them, and to their use in therapy, in particular their use in the prophylaxis and treatment of respiratory diseases. 1

  本发明涉及公式(I)的新化合物，其制造方法，包含它们的制药组合物以及它们在治疗中的应用，特别是在呼吸系统疾病的预防和治疗中的应用。
• Derivatives of 4-(2-amino -1-hydroxyethyl)phenol as agonists of the Beta2 adrenergic receptor
  申请人：Duran Carlos Puig

  公开号：US20090042933A1

  公开（公告）日：2009-02-12

  A compound of formula (I) or a pharmaceutically-acceptable salt, solvate or stereoisomer thereof wherein R 1 is a group chosen from —CH 2 OH and —NHC(O)H; R 2 is a hydrogen atom or R 1 together with R 2 form the group —NH—C(O)—CH═CH—, wherein the nitrogen atom is bound to the carbon atom in the phenyl ring holding R 1 and the carbon atom is bound to the carbon atom in the phenyl ring holding R 2 ; R 3 is chosen from a hydrogen atom, a halogen atom and groups chosen from —SO—R 5 , —SO 2 —R 5 , —NH—CO—NH 2 , —CO—NH 2 , hydantoino, C 1-4 alkyl, C 1-4 alkoxy and —SO 2 NR 5 R 6 ; R 4 is chosen from a hydrogen atom, a halogen atom and a C 1-4 alkyl group; R 5 is chosen from a C 1-4 alkyl group and a C 3-8 cycloalkyl group; R 6 is independently chosen from a hydrogen atom and a C 1-4 alkyl group; n, p and q are independently 0, 1, 2, 3 or 4; m and s are independently 0, 1, 2 or 3; and r is 0, 1 or 2 with the provisos that at least one of m and r is not 0, the sum n+m+p+q+r+s is 7, 8, 9, 10, 11, 12 or 13, and the sum q+r+s is 2, 3, 4, 5 or 6.

  化合物的化学式（I）或其药学上可接受的盐、溶剂化合物或立体异构体，其中R1是从—CH2OH和—NHC（O）H中选择的基团；R2是氢原子或R1与R2一起形成—NH—C（O）—CH═CH—的基团，其中氮原子与持有R1的苯环中的碳原子结合，碳原子与持有R2的苯环中的碳原子结合；R3从氢原子、卤原子和从—SO—R5、—SO2—R5、—NH—CO—NH2、—CO—NH2、hydantoino、C1-4烷基、C1-4烷氧基和—SO2NR5R6中选择的基团；R4从氢原子、卤原子和C1-4烷基中选择；R5从C1-4烷基和C3-8环烷基中选择；R6独立选择从氢原子和C1-4烷基中选择；n、p和q独立选择0、1、2、3或4；m和s独立选择0、1、2或3；r为0、1或2，但至少有一个m和r不为0，n+m+p+q+r+s之和为7、8、9、10、11、12或13，且q+r+s之和为2、3、4、5或6。
• Derivatives of 4-(2-Amino-1-Hydroxyethyl) Phenol as Agonists of the Beta2 Adrenergic Receptor
  申请人：PUIG DURAN Carlos

  公开号：US20120101075A2

  公开（公告）日：2012-04-26

  The present disclosure relates to 4-(2-amino-1-hydroxyethyl)phenol derivatives of formula (I) as well as pharmaceutical compositions comprising them, and their use in therapy as agonists of the BETA2 adrenergic receptor.

  本公开涉及式(I)的4-(2-氨基-1-羟乙基)苯酚衍生物，以及包含它们的药物组合物，以及它们作为BETA2肾上腺素能受体激动剂在治疗中的使用。
• DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTOR
  申请人：Tanã Jordi Bach

  公开号：US20100168161A1

  公开（公告）日：2010-07-01

  The present relates to compounds of formula (I): or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. The present disclosure also relates to pharmaceutical compositions comprising the compounds of formula (I), and to their methods of use in therapy.

  本发明涉及式(I)的化合物：或其药学上可接受的盐、溶剂合物或立体异构体。本公开还涉及包含式(I)化合物的制药组合物，以及它们在治疗中的使用方法。